anthrax
euronet
coordin
action
eu
framework
programm
design
strengthen
network
activ
anthrax
research
group
europ
harmonis
protocol
test
anthrax
vaccin
therapeut
inevit
project
also
address
aspect
current
polit
issu
biosecur
dualus
research
ie
research
agent
import
diseas
man
livestock
agricultur
could
use
agent
bioterror
review
provid
comprehens
overview
biolog
bacillu
anthraci
pathogenesi
epidemiolog
diagnosi
anthrax
well
vaccin
therapeut
intervent
strategi
propos
requir
code
conduct
work
dualus
agent
anthrax
bacillu
also
discuss
year
mark
birth
medic
microbiolog
year
robert
koch
koch
describ
definit
aetiolog
anthrax
koch
fig
perform
research
earli
complet
unknown
taken
posit
district
medic
offic
wollstein
wolsztyn
poland
long
work
day
devot
hobbi
microscopi
microb
work
home
small
room
adjoin
medic
practic
koch
neither
first
find
rodlik
microorgan
blood
anim
die
anthrax
first
transfer
diseas
fresh
dri
blood
contain
rodlik
corpuscl
lord
witkowski
parish
nevertheless
eleg
work
first
demonstr
unequivoc
rodlik
microorgan
consist
present
blood
tissu
diseas
anim
spore
develop
starvat
condit
spore
could
transform
rodlik
bacilli
nutrientrich
condit
rodlik
organ
could
cultur
pure
form
final
cultur
materi
either
form
rodlik
microorgan
spore
caus
anthrax
diseas
experiment
infect
anim
meticul
work
includ
vitro
cultur
microscopi
anim
experi
koch
conclud
spore
form
surviv
long
period
time
even
cadav
inter
soil
spore
could
dissemin
diseas
long
outbreak
anthrax
koch
work
establish
strategi
microb
hunter
led
birth
medic
microbiolog
late
centuri
basi
later
call
koch
postul
reproduc
identif
agent
diseas
tissu
vitro
cultur
agent
pure
form
transfer
pure
cultur
materi
elicit
diseas
experiment
anim
time
loui
pasteur
pasteur
director
laboratori
physiolog
chemistri
cole
normal
pari
alreadi
famou
father
figur
microbiolog
fig
pasteur
provid
conclus
evid
wide
held
theori
spontan
gener
life
specif
demonstr
heat
materi
remain
steril
access
outsid
environ
prevent
readili
becam
vital
access
given
environment
microb
typic
pasteur
restrict
fundament
research
instead
saw
work
context
applic
exampl
context
ferment
wine
beer
ferment
koch
koch
right
loui
pasteur
pasteur
left
inset
draw
b
anthraci
robert
koch
togeth
ferdinand
cohn
made
differ
putrefact
henc
link
infecti
diseas
soon
becam
obviou
pasteur
interest
increasingli
focus
infecti
diseas
perform
seri
experi
establish
unequivoc
bacterium
accompani
element
caus
diseas
therebi
confirm
robert
koch
conclus
pasteur
perform
one
famou
experi
public
anthrax
vaccin
trial
farmyard
pouillylefort
se
pari
sheep
gather
half
vaccin
cultur
pasteur
attenu
bacillu
anthraci
wherea
half
remain
unvaccin
four
week
later
presenc
larg
crowd
interest
observ
sheep
inocul
cultur
virul
anthrax
bacilli
pasteur
return
farmyard
day
later
applaud
crowd
spectat
vaccin
sheep
aliv
one
ewe
look
unhealthi
later
succumb
unrel
diseas
contrast
unvaccin
anim
alreadi
dead
rest
die
shortli
afterward
pasteur
although
method
use
prepar
attenu
cultur
safeti
later
becam
matter
controversi
experi
scientif
success
landmark
control
vaccin
trial
also
exemplari
rais
public
awar
benefici
result
biomed
research
pasteur
vaccin
effect
worldwid
use
instrument
reduc
burden
anthrax
livestock
inde
pasteur
institut
franc
across
world
larg
found
fund
revenu
gener
pasteur
anthrax
vaccin
koch
pasteur
would
probabl
greatli
dishearten
discov
often
microb
b
anthraci
help
establish
modern
medic
microbiolog
vaccinolog
also
misus
uneth
goal
exampl
japanes
armi
infam
unit
base
manchuria
experiment
infect
prison
b
anthraci
british
armi
conduct
anthrax
bioweapon
test
gruinard
island
scotland
also
prepar
huge
quantiti
cattl
cake
contamin
anthrax
spore
dispers
aircraft
german
agricultur
land
fortun
latter
weapon
never
use
april
sverdlovsk
former
soviet
union
yekaterinburg
russia
anthrax
outbreak
document
least
case
human
diseas
die
result
accident
releas
spore
bioweapon
research
product
facil
final
aftermath
terror
attack
world
trade
center
new
york
septemb
anthrax
attack
report
along
east
coast
usa
distribut
least
five
letter
contain
small
quantiti
fine
dispers
anthrax
spore
attack
result
confirm
anthrax
case
inhal
anthrax
die
case
cutan
anthrax
inglesbi
et
al
moreov
individu
treat
prophylact
antibiot
numer
public
build
decontamin
labori
procedur
perpetr
bioterrorist
crime
caught
despit
massiv
investig
polic
intellig
servic
bacillu
anthraci
mention
appendix
convent
prohibit
develop
product
stockpil
bacteriolog
biolog
toxin
weapon
destruct
short
biolog
weapon
convent
bwc
bwc
open
signatur
april
enter
forc
march
mostli
aim
regul
interst
activ
june
signatori
ratif
access
whilst
signatori
yet
ratifi
convent
regrett
state
remain
nonsignatori
bwc
bioterrorist
attack
b
anthraci
made
clear
regul
activ
state
insuffici
individu
attack
eg
bioterrorist
purpos
need
consid
depth
usa
drawn
conclus
led
massiv
financi
support
biodef
research
also
formul
us
patriot
act
format
depart
homeland
secur
new
administr
deal
biodef
matter
format
nation
scienc
advisori
board
biosecur
advis
govern
scientif
dualus
issu
center
diseas
control
prevent
cdc
atlanta
usa
issu
list
biolog
weapon
includ
b
anthraci
categori
compris
microb
highest
risk
easili
dissemin
transmit
high
mortal
cdc
new
legisl
work
select
agent
becom
tightli
control
major
limit
select
staff
access
categori
agent
facil
work
agent
occur
dissemin
sensit
scientif
inform
proscript
distribut
requir
intern
level
usa
strongli
endors
format
review
confer
state
parti
bwc
intern
forum
discuss
code
conduct
work
dualus
organ
review
confer
took
place
conclud
meet
decemb
bwc
european
level
dilemma
work
dualus
organ
approach
well
consortia
form
within
eu
framework
programm
minut
financi
support
comparison
usa
effort
one
first
consortia
fund
anthrax
euronet
wwwanthraxeuronetorg
coordin
action
aim
strengthen
network
activ
field
anthrax
research
harmonis
protocol
test
anthrax
vaccin
therapeut
develop
project
also
address
aspect
dualus
polit
issu
relat
biosecur
ozin
et
al
paper
particip
anthrax
euronet
provid
comprehens
overview
biolog
b
anthraci
pathogenesi
epidemiolog
anthrax
well
novel
diagnost
tool
earli
detect
anthrax
new
intervent
strategi
build
earlier
review
mock
fouet
koehler
moreov
summaris
conclus
review
confer
initi
anthrax
euronet
consortium
code
conduct
work
dualus
organ
critic
import
work
anthrax
highrisk
pathogen
much
achiev
sinc
time
koch
pasteur
would
probabl
agre
lot
excit
scienc
still
done
field
anthrax
research
continu
invest
develop
knowledg
necessari
come
year
order
improv
acceler
develop
necessari
countermeasur
term
vaccin
therapeut
improv
diagnost
tool
anthrax
inde
emerg
newli
emerg
diseas
concept
possibl
develop
intern
code
conduct
bind
biosecur
measur
seem
inevit
result
dualus
dilemma
work
anthrax
highrisk
pathogen
scientist
slow
deflect
issu
research
highrisk
agent
inde
critic
part
dialogu
part
solut
bacillu
anthraci
agent
diseas
anim
model
diseas
earli
stage
infect
anthrax
primarili
diseas
herbivor
although
mammal
includ
human
suscept
b
anthraci
spore
enter
host
cutan
gastrointestin
pulmonari
rout
progress
fatal
system
anthrax
whatev
rout
infect
believ
b
anthraci
spore
transport
macrophag
origin
site
inocul
drain
lymph
node
spore
germin
give
rise
veget
bacilli
produc
princip
virul
factor
toxin
capsul
infect
extend
success
node
bacilli
enter
blood
stream
continu
multipli
rapidli
secret
toxin
reach
remark
high
number
host
succumb
shocklik
death
bacilli
shed
die
dead
anim
sporul
contact
air
contamin
local
new
cycl
may
begin
anthrax
therefor
associ
toxaemia
rapidli
spread
infect
evolv
septicaemia
control
prevent
must
take
aspect
account
togeth
measur
deal
resili
spore
anthrax
cours
danger
infect
man
order
minimis
risk
exposur
staff
environment
dissemin
mandatori
countri
handl
agent
infect
anim
safe
primari
contain
use
socal
biolog
contain
level
procedur
restrict
access
stock
agent
practic
staff
afford
addit
protect
vaccin
measur
also
limit
access
agent
intent
crimin
misus
includ
bioterror
strain
mutant
lack
abil
produc
capsul
highli
attenu
therefor
countri
strain
subject
restrict
fulli
virul
wildtyp
strain
b
anthraci
carri
two
larg
plasmid
kb
respect
carri
gene
encod
primari
virul
factor
toxin
capsul
respect
complet
chromosom
plasmid
dna
sequenc
multipl
strain
avail
public
databas
two
anthrax
toxin
deriv
combin
three
differ
protein
protect
antigen
pa
kda
oedema
factor
ef
kda
lethal
factor
lf
kda
pa
bind
two
cell
surfac
receptor
tumour
endothelium
marker
capillari
morphogenesi
protein
wide
express
mani
cell
type
includ
immun
cell
collier
young
scobi
young
recent
lowdens
lipoprotein
receptorrel
protein
implic
pa
coreceptor
essenti
ef
lf
endocytosi
wei
et
al
other
confirm
find
young
et
al
proteolyt
releas
ctermin
domain
kda
pa
result
spontan
oligomeris
truncat
pa
pa
heptam
pa
bind
ef
lf
collier
young
pa
ef
pa
lf
complex
enter
raft
endocytot
uptak
transport
late
endosom
whose
low
ph
induc
conform
chang
complex
insert
part
pa
membran
transloc
ef
lf
cytosol
abrami
et
al
dal
molin
et
al
ef
calmodulindepend
adenyl
cyclas
leppla
creat
gradient
camp
high
concentr
perinuclear
area
whilst
lf
metalloproteas
cleav
isoform
mapkk
mek
throughout
cytosol
vital
et
al
exclud
may
act
cytosol
protein
suggest
recent
report
lf
act
inflammasom
boyden
dietrich
muehlbauer
et
al
mek
part
major
signal
pathway
link
activ
membran
receptor
transcript
sever
gene
includ
encod
proinflammatori
cytokin
protein
involv
immun
respons
capsul
linear
polym
gdglutam
acid
consid
major
virul
factor
b
anthraci
capsul
contribut
pathogen
enabl
bacteria
resist
phagocytosi
macrophag
thu
evad
host
immun
defenc
promot
septicaemia
addit
capsul
weakli
immunogen
host
react
differ
virul
factor
b
anthraci
strain
lack
either
two
virul
plasmid
consid
nonpathogen
human
howev
mice
appear
much
affect
replic
encapsul
bacteria
compar
resist
toward
action
toxin
differ
strain
mice
exhibit
differ
degre
suscept
toward
infect
b
anthraci
reflect
quit
dissimilar
number
bacteri
spore
need
lethal
experiment
group
certain
inbr
strain
laboratori
mice
aj
mice
highli
suscept
toxigen
nonencapsul
strain
b
anthraci
stern
anim
succumb
effect
high
level
anthrax
toxin
secret
infect
phenomenon
link
defici
complement
system
strain
mice
welko
friedland
lead
unrestrict
bacteri
growth
initi
stage
vaccin
research
potenti
vaccin
candid
typic
assess
immunogen
usual
outbr
mous
strain
use
answer
basic
immunolog
question
subsequ
stage
potenti
vaccin
must
test
protect
efficaci
challeng
studi
suitabl
anim
model
includ
aj
mice
infect
toxinogen
noncapsul
strain
b
anthraci
outbr
mice
guinea
pig
rabbit
infect
fulli
virul
strain
b
anthraci
correl
protect
efficaci
anim
model
expect
outcom
human
rabbit
current
appear
suitabl
small
anim
model
rabbit
suscept
infect
virul
strain
b
anthraci
whilst
rel
resist
stern
carbosap
attenu
vaccin
strain
contrast
mice
guinea
pig
suscept
carbosap
vaccin
strain
depend
mous
strain
stern
vaccin
strain
whilst
guinea
pig
suscept
carbosap
vaccin
strain
fasanella
et
al
thu
pathway
anthrax
pathogenesi
mice
guinea
pig
differ
rabbit
rabbit
nonhuman
primat
consid
appropri
anim
studi
biomark
immun
protect
human
phipp
et
al
anthrax
toxin
host
immun
respons
b
anthraci
trigger
strong
inflammatori
respons
activ
tolllik
receptor
polymorphonuclear
cell
macrophag
site
entri
host
hsu
et
al
mayerschol
et
al
lf
ef
synergist
interfer
process
affect
two
signal
pathway
crosstalk
essenti
full
induct
oxid
burst
proinflammatori
cytokin
express
cell
migrat
baldari
et
al
among
firstlin
effector
innat
immun
system
may
involv
bactericid
activ
group
iia
secret
phospholipas
spla
iia
found
kill
b
anthraci
vitro
ex
vivo
piri
gimenez
et
al
furthermor
transgen
mice
express
human
spla
iia
exhibit
extrem
high
level
protect
anthrax
vivo
administr
recombin
spla
iia
significantli
protect
spla
iiadefici
mice
b
anthraci
infect
pirisgimenez
et
al
owe
widespread
distribut
pa
receptor
ef
lf
act
immun
cell
involv
innat
adapt
immun
respons
baldari
et
al
promot
apoptosi
dendrit
cell
macrophag
chang
membran
permeabl
dissip
mitochondri
membran
potenti
dna
fragment
toxin
sensit
cell
appear
link
differ
genet
background
via
polymorph
compon
inflammasom
boyden
dietrich
lf
suppress
express
proinflammatori
cytokin
tnfa
surfac
activ
marker
induc
lipopolysaccharid
peptidoglycan
dendrit
cell
baldari
et
al
accordingli
dendrit
cell
infect
toxigen
strain
b
anthraci
show
differ
cytokin
secret
profil
compar
cell
infect
nontoxigen
strain
tournier
et
al
splenocyt
recognis
spore
pathway
involv
none
known
tolllik
receptor
nod
protein
upon
interact
spore
macrophag
secret
stimul
natur
killer
cell
secret
ifng
lt
inhibit
secret
cytokin
glomski
et
al
ifng
seem
play
signific
role
immun
b
anthraci
infect
mice
defici
ifng
signal
sensit
infect
wildtyp
counterpart
glomski
et
al
anthrax
toxin
also
act
b
lymphocyt
baldari
et
al
paccani
et
al
fang
et
al
although
function
impair
antigenpres
cell
would
appear
suffici
achiev
goal
pathogen
impair
cellular
compon
adapt
immun
respons
addit
anthrax
toxin
found
inhibit
chemotaxi
immun
cell
find
may
relev
explain
long
time
requir
clear
infect
site
skin
anthrax
rossipaccani
et
al
activ
like
littl
role
rapid
pathogenesi
inhal
anthrax
whilst
relev
much
common
slower
develop
cutan
anthrax
emerg
pictur
b
anthraci
develop
multitarget
strategi
aim
neutralis
cellular
compon
innat
immun
compart
via
combin
action
two
toxin
affect
crucial
gener
step
cell
signal
camp
map
kinas
pathway
sever
point
intersect
baldari
et
al
b
anthraci
gramposit
rodshap
aerob
soil
bacterium
like
bacillu
speci
form
spore
respons
starvat
matur
spore
metabol
inact
highli
order
structur
resist
extrem
temperatur
radiat
desicc
harsh
chemic
physic
damag
see
mock
fouet
properti
allow
spore
surviv
persist
sever
decad
soil
encount
environment
condit
favour
germin
gener
entri
spore
mammalian
host
initi
event
anthrax
infect
spore
infect
host
via
cutan
inocul
ingest
inhal
surfac
spore
repres
first
point
contact
host
defenc
target
identifi
specif
detect
marker
much
interest
structur
composit
spore
b
anthraci
close
relat
speci
b
cereu
b
thuringiensi
possess
exosporium
outermost
structur
surround
matur
spore
consist
paracrystallin
basal
layer
hairlik
outer
layer
compos
protein
lipid
carbohydr
contain
sever
protein
synthesis
concomitantli
cortex
coat
one
b
anthraci
exosporium
glycoprotein
bcla
structur
compon
hairlik
filament
identifi
sylvestr
et
al
bcla
contain
central
region
similar
mammalian
collagen
protein
collagen
region
consist
gxx
collagenlik
triplet
includ
larg
proport
gpt
triplet
number
gxx
repeat
vari
consider
strain
variat
respons
vari
length
filament
nap
cover
outer
layer
exosporium
sylvestr
et
al
spore
bcla
mutant
strain
total
devoid
filament
sylvestr
et
al
howev
structur
exosporium
crystallin
basal
layer
unchang
crystallin
organis
observ
inner
outer
surfac
basal
layer
sylvestr
et
al
sever
protein
describ
present
tightli
associ
exosporium
role
structur
function
organis
exosporium
remain
elucid
two
exosporium
protein
exsfa
exsfb
requir
localis
bcla
spore
surfac
contribut
stabil
exosporium
crystallin
layer
sylvestr
et
al
steichen
et
al
bcla
immunodomin
protein
spore
surfac
first
structur
interact
host
cell
therefor
may
play
role
infect
process
andor
protect
immun
respons
mice
immunis
spore
b
anthraci
either
aliv
inactiv
develop
strong
respons
bcla
appear
major
band
recognis
polyclon
antibodi
western
blot
less
immunogen
protein
includ
exsi
coti
exsf
also
detect
sylvestr
et
al
sylvestr
et
al
redmond
et
al
monoclon
antibodi
rais
spore
recognis
epitop
bcla
specif
b
anthraci
repres
use
detect
tool
steichen
et
al
sylvestr
et
al
delet
bcla
stern
strain
virul
b
anthraci
strain
affect
virul
mice
either
subcutan
intranas
administr
spore
sylvestr
et
al
sylvestr
et
al
also
bcla
delet
mutant
ame
strain
retain
full
virul
guinea
pig
mice
bozu
et
al
anim
studi
livespor
vaccin
protect
pa
alon
therefor
adapt
immun
anthrax
depend
sole
control
toxaemia
antipa
neutralis
antibodi
addit
formaldehydeinactiv
spore
fi
pa
shown
confer
full
protect
highli
virul
strain
b
anthraci
mous
guinea
pig
model
infect
brossier
et
al
involv
specif
spore
antigen
protect
mechan
immun
respons
spore
studi
bcladefici
fi
shown
effect
parent
strain
induc
protect
sylvestr
et
al
spore
antigen
induc
strong
immun
respons
humor
cellular
sporereact
lymphocyt
shown
protect
absenc
toxaemia
glomski
et
al
b
see
although
anthrax
essenti
control
industrialis
world
remain
seriou
zoonosi
develop
world
enzoot
mani
natur
park
histor
diseas
long
recognis
even
specul
anthrax
plagu
describ
plagu
egypt
describ
bibl
exodu
anthrax
one
major
caus
mortal
domest
livestock
record
histori
exampl
max
stern
father
modern
attenu
veterinari
anthrax
vaccin
see
describ
major
livestock
mortal
south
africa
estim
anim
lost
anthrax
stern
develop
improv
vaccin
stern
improv
regul
anim
trade
includ
quarantin
led
drastic
declin
incid
anthrax
countri
nation
control
programm
work
well
diseas
inde
anthrax
today
consid
uncommon
diseas
western
europ
northern
america
australia
except
endem
foci
wild
fauna
nation
park
hughjon
exampl
canada
situat
control
except
epidem
bison
popul
mackenzi
bison
sanctuari
wood
bison
nation
park
nishi
et
al
wherea
usa
diseas
sporad
area
hyperendem
southwest
texa
hughjon
australia
anthrax
sporad
although
sudden
sever
epidem
occur
northern
victoria
turner
et
al
europ
major
endem
area
greec
turkey
albania
probabl
balkan
hughjon
franc
itali
continu
record
sporad
outbreak
fouet
et
al
fasanella
et
al
lack
suitabl
control
programm
central
asia
south
america
africa
make
diseas
common
contin
central
south
america
lack
effect
control
programm
hyperendem
anthrax
zone
guatemala
el
salvador
endem
zone
mexico
hondura
nicaragua
costa
rica
brazil
venezuela
hughjon
contrast
vaccin
programm
uruguay
chile
result
good
control
russia
countri
former
soviet
union
lack
effect
control
programm
evidenc
high
percentag
human
case
reflect
inadequaci
public
health
system
veterinari
servic
hughjon
asia
anthrax
widespread
philippin
south
korea
south
east
india
western
mountain
zone
china
mongolia
papua
new
guinea
porcin
anthrax
report
frequent
hughjon
africa
remain
sever
afflict
major
epidem
area
wildlif
area
queen
elizabeth
nation
park
uganda
b
anthraci
usual
affect
anim
pastur
infect
mammal
human
accident
host
vitro
experi
suggest
b
anthraci
live
reproduc
like
soil
saprophyt
rhizospher
grass
plant
sail
koehler
howev
studi
decad
suggest
unlik
import
mode
spore
amplif
natur
soil
veget
cell
b
anthraci
releas
bodi
fluid
infect
dead
anim
sporul
rapidli
contact
air
lead
widespread
contamin
surround
soil
pastur
longev
spore
contamin
soil
well
document
inde
spore
b
anthraci
isol
bone
anim
die
year
ago
kruger
nation
park
de
vo
scaveng
anim
blowfli
dissemin
spore
long
distanc
environ
may
infect
suscept
mammal
outbreak
typic
occur
raini
season
caus
soil
disturb
follow
dri
season
topographi
land
import
downhil
field
potenti
danger
uphil
field
due
runoff
calciumrich
alkalin
soil
promot
persist
spore
soil
rel
humusrich
acid
soil
appropri
manag
outbreak
includ
prompt
complet
inciner
carcass
rather
burial
togeth
prompt
case
recognit
vaccin
suscept
livestock
anthrax
infecti
diseas
per
se
outbreak
typic
consist
sporad
case
occur
within
restrict
area
nevertheless
anthrax
epidem
sometim
occur
exampl
one
kill
hippopotami
luangwa
valley
zambia
june
novemb
turnbul
et
al
epidem
mackenzi
bison
sanctuari
canada
sever
thousandstrong
bison
popul
die
hughjon
de
vo
fli
probabl
play
import
role
mechan
transport
b
anthraci
although
mechan
clearli
understood
anthrax
associ
season
tabanid
fli
activ
possibl
role
haematobia
irritan
tabanu
spp
spread
anthrax
describ
scientif
literatur
almost
centuri
ago
mitzmain
morri
epidem
anthrax
edward
plateau
texa
involv
domest
wild
speci
anim
especi
deer
hughjon
de
vo
characterist
spread
diseas
suggest
insect
tabanid
haematophagu
insect
could
play
import
role
widespread
transmiss
diseas
similar
associ
seen
sever
epidem
anthrax
victoria
australia
januari
march
turner
et
al
analysi
anthrax
epidem
show
common
risk
factor
includ
previou
histori
epidem
area
suspens
vaccin
programm
give
rise
high
level
suscept
anthraxlik
ill
report
wild
nonhuman
primat
live
tropic
rainforest
habitat
previous
known
harbour
b
anthraci
leendertz
et
al
characteris
unusu
high
number
sudden
death
observ
month
three
commun
wild
chimpanze
pan
troglodyt
tai
nation
park
ivori
coast
howev
bacillu
strain
associ
outbreak
encapsul
toxigen
b
cereu
typic
b
anthraci
find
fli
play
import
role
spread
anthrax
outbreak
support
presenc
profus
number
fli
carcass
affect
chimpanze
particularli
bodili
part
bloodi
effus
laboratori
studi
use
mous
guinea
pig
model
shown
stomoxi
calcitran
aed
aegypti
taeniorhynchu
capabl
transmit
anthrax
although
transmiss
rate
rel
low
fli
mosquito
suspect
high
popul
densiti
bite
insect
could
import
vehicl
spread
diseas
turrel
knudson
antibodi
b
anthraci
toxin
detect
unvaccin
herbivor
graze
anthrax
risk
area
fasanella
et
al
consist
subclin
exposur
anthrax
bacilli
spore
graze
fli
bite
protect
effect
lowlevel
immun
respons
unclear
even
immun
respons
vaccin
may
insuffici
protect
anim
environment
concentr
spore
high
immun
memori
sternetyp
anim
vaccin
may
poor
regular
vaccin
requir
highendem
epidem
area
togeth
prompt
diagnosi
appropri
carcass
destruct
diagnosi
anthrax
made
combin
microscop
cultur
molecularbiolog
investig
case
specif
clinic
symptom
eg
oedema
format
eschar
microscop
detect
encapsul
gramposit
rod
blood
may
consid
pathognomon
particular
rout
infect
predispos
one
septicaem
progress
inhal
intestin
anthrax
gener
result
pure
cultur
high
cell
count
affect
organ
correspond
lymph
node
blood
characterist
coloni
morpholog
nonhaemolyt
growth
blood
agar
nonmotil
gramposit
rod
sensit
gamma
phage
penicillin
format
capsul
specif
condit
vitro
within
host
bodi
indic
b
anthraci
howev
even
bacterium
isol
anthraxlik
diseas
fit
scheme
b
anthracisspecif
virul
gene
code
lethal
toxin
oedema
toxin
capsul
still
present
hoffmast
et
al
klee
et
al
contrast
clinic
sampl
environment
sampl
usual
consist
natur
compet
bacteri
fungal
protozoan
flora
may
also
contain
variou
chemic
substanc
togeth
separ
influenc
germin
spore
b
anthraci
propag
veget
form
vitro
occasion
propag
inhibit
vitro
lead
neg
cultur
pcr
result
artifici
cultiv
condit
use
laboratori
b
anthraci
rapidli
overgrown
faster
replic
competit
soiland
plantassoci
bacteria
although
select
cultur
media
suppress
much
compet
flora
complet
suppress
growth
common
soil
bacillu
speci
includ
b
megaterium
cultur
detect
confirm
b
anthraci
grow
blood
agar
incub
overnight
rough
dri
nonpig
coloni
mm
diamet
greywhit
powderlik
appear
although
specif
b
anthraci
typic
coloni
often
describ
tacki
highli
viscou
consist
consequ
format
long
chain
cultur
condit
use
preliminari
criterion
diagnost
screen
sometim
curli
tail
edg
coloni
socal
medusa
head
trait
also
seen
b
cereu
b
thuringiensi
strain
b
megaterium
therefor
definit
criterion
differenti
latter
speci
howev
elicit
strong
haemolysi
distinguish
b
anthraci
therefor
bloodcontain
media
prefer
comparison
often
use
plet
agar
knisli
tspb
agar
made
highli
select
gramneg
bacteria
supplement
trimethoprim
mgl
sulfamethoxazol
mgl
polymyxin
b
iul
howev
import
note
coloni
b
anthraci
grow
within
lysi
zone
haemolyt
bacillu
spp
differenti
macroscop
lead
falseneg
assess
environment
sampl
investig
complex
sampl
materi
origin
sampl
must
alway
accompani
parallel
aliquot
materi
artifici
contamin
spike
defin
number
spore
avirul
strain
b
anthraci
exampl
commerci
avail
vaccin
strain
stern
addit
origin
spike
sampl
incub
liquid
enrich
broth
analys
semiselect
solid
media
thereaft
lysi
veget
cell
b
anthraci
gamma
phage
long
accept
highli
specif
diagnost
criterion
although
rare
except
exist
marston
et
al
accord
abshir
et
al
plaqu
format
influenc
concentr
phage
suspens
use
densiti
bacteri
lawn
presenc
virul
plasmid
high
low
densiti
bacteria
may
lead
falseneg
result
falseposit
read
may
result
uneven
bacteri
lawn
diagnost
anim
trial
may
becom
necessari
sampl
yield
posit
suspici
pcr
result
accompani
neg
noninterpret
cultur
test
ii
environment
sampl
show
inhibit
growth
b
anthraci
medium
use
detect
iii
determin
virul
isol
infect
mice
ml
suspens
heat
min
administ
dorsal
subcutan
inject
environment
sampl
use
import
mice
immunis
clostridi
toxin
virul
b
anthraci
present
sampl
anim
die
within
day
depend
dose
phase
nonspecif
symptom
system
infect
promin
patholog
featur
anthrax
pathogenesi
subcutan
oedema
around
infect
site
increas
amount
liquid
abdomin
caviti
mice
die
shed
blood
bodi
orific
presenc
b
anthraci
caus
death
must
verifi
cultur
andor
molecular
diagnosi
although
attempt
made
decad
develop
immunolog
test
detect
cellderiv
toxin
antigen
still
test
kit
avail
commerci
exist
antibodi
reagent
identif
b
anthraci
often
limit
abil
distinguish
b
anthraci
relat
environment
ubiquit
speci
longchamp
leighton
rapid
test
kit
use
monoclon
antibodi
microfluid
develop
andor
avail
militari
sector
pcr
method
choic
parallel
diagnost
test
whether
perform
directli
clinic
sampl
nonselect
enrich
mix
cultur
confirm
test
suspici
coloni
addit
becom
necessari
clarif
neg
cultur
result
artifici
contamin
control
sampl
spike
sampl
ii
spike
agar
plate
uninterpret
due
overgrowth
b
anthraci
haemolys
bacillu
spp
confirm
suspici
coloni
brief
boil
min
resuspend
coloni
buffer
suffici
extract
dna
compat
pcr
prepar
dna
nonselect
enrich
cultur
dna
prepar
kit
gener
give
better
result
dna
prepar
directli
spore
simpl
heat
autoclav
high
number
spore
present
howev
low
number
spore
present
expect
case
nose
swab
secondari
contamin
scenario
dna
prepar
preced
spore
germin
cultur
identifi
virul
b
anthraci
strain
differenti
nonvirul
strain
presenc
virul
plasmid
toxin
capsul
format
must
evalu
neg
pcr
result
diagnost
posit
neg
control
reaction
unambigu
howev
posit
pcr
result
alway
accompani
isol
bacterium
caus
pcr
signal
necessari
aid
anim
experi
latter
requir
respons
pcr
target
publish
far
detect
plasmid
b
anthraci
may
lead
isol
plasmidcarri
strain
belong
group
b
anthraci
sensu
stricto
okinaka
et
al
nevertheless
strain
shown
respons
albeit
rare
sever
anthraxlik
diseas
hoffmast
et
al
klee
et
al
uncertainti
connect
presenc
virul
plasmid
reliabl
chromosom
marker
b
anthraci
desir
howev
publish
chromosom
target
rpob
slayer
protein
gene
often
lead
falseposit
result
environment
sampl
papaparaskeva
et
al
altern
chromosom
target
sasp
gene
describ
beyer
et
al
isol
b
anthraci
collect
across
world
show
extrem
high
genet
homolog
past
made
phylogenet
forens
characteris
isol
convent
method
rather
limit
valu
modern
molecular
fingerprint
techniqu
base
analysi
multipl
loci
variabl
number
tandem
repeat
sequenc
socal
canon
singlenucleotid
polymorph
contribut
rapid
advanc
understand
popul
genet
b
cereu
group
b
anthraci
particular
enabl
precis
molecular
epidemiolog
investig
outbreak
lead
specif
characteris
isol
keim
et
al
lista
et
al
method
necessarili
restrict
specialis
laboratori
present
although
detail
discuss
studi
beyond
scope
review
reader
refer
two
recent
report
illustr
power
genom
relat
molecular
analys
van
ert
et
al
tourass
et
al
contribut
largescal
genom
comparison
make
understand
popul
dynam
ecolog
pathogen
inde
approach
also
hold
promis
develop
highli
discriminatori
diagnost
target
even
therapeut
target
current
singl
diagnost
method
consid
suffici
valid
therefor
samplebas
combin
diagnost
procedur
alway
necessari
everi
laboratori
train
expert
routin
diagnost
procedur
pcr
microscopi
cultur
screen
method
abl
make
preliminari
diagnosi
procedur
aim
confirm
diagnosi
b
anthraci
requir
higher
level
expertis
therefor
perform
specialis
laboratori
princip
methodolog
approach
investig
complex
sampl
materi
shown
flow
diagram
fig
livespor
vaccin
veterinari
vaccin
use
loui
pasteur
immunis
livestock
one
first
vaccin
develop
consist
attenu
strain
b
anthraci
result
repeat
cultur
day
elev
temperatur
cultur
use
pasteur
probabl
contain
mixtur
bacilli
capsuleencod
plasmid
bacilli
complet
plasmid
although
pasteur
vaccin
strain
show
reduc
virul
compar
wildtyp
b
anthraci
variat
degre
protect
virul
batch
result
occasion
death
vaccin
anim
basi
attenu
remain
mysteri
year
mikesel
et
al
show
increas
cultur
temperatur
result
partial
loss
toxinencod
plasmid
nowaday
live
spore
attenu
nonencapsul
stern
strain
commonli
use
immunis
anim
strain
prepar
max
stern
south
africa
late
stern
stabl
acapsul
mutant
produc
three
toxin
compon
b
anthraci
pa
lf
ef
ie
possess
plasmid
lack
plasmid
respons
capsul
format
livespor
vaccin
prove
safe
effect
induc
profound
antibodi
respons
pa
b
anthraci
singl
dose
provid
immun
year
repeat
vaccin
requir
longterm
protect
stern
vaccin
complet
avirul
anim
speci
includ
human
although
residu
virul
observ
goat
laboratori
anim
addit
pasteur
stern
vaccin
strain
livespor
vaccin
carri
plasmid
yet
still
attenu
includ
italian
carbosap
strain
argentinean
strain
reason
attenu
remain
clarifi
immunis
human
live
spore
use
countri
eg
former
soviet
union
china
exampl
strain
similar
stern
strain
regard
plasmid
pattern
virul
properti
licens
use
anthrax
vaccin
human
earli
studi
investig
protect
anim
transmiss
oedema
fluid
indic
exist
solubl
factor
confer
protect
gladston
demonstr
presenc
protect
antigen
cultur
b
anthraci
gladston
work
led
develop
two
similar
distinct
protein
vaccin
licens
still
use
usa
uk
vaccin
produc
uk
vaccin
use
sinc
prepar
cultur
stern
strain
supernat
static
cultur
grown
protein
hydrolys
medium
contain
charcoal
precipit
potassium
aluminium
sulphat
alum
preserv
thiomers
three
toxin
compon
present
vaccin
although
pa
predomin
antigen
immun
respons
direct
predominantli
pa
lf
us
food
drug
administr
licens
ava
anthrax
vaccin
adsorb
known
biothrax
tm
sinc
consist
aluminium
hydroxid
alhydrogel
adsorb
cultur
filtrat
avirul
strain
main
antigen
vaccin
pa
formaldehyd
ad
stabilis
benzethonium
chlorid
preserv
two
licens
acellular
vaccin
shown
protect
sever
anim
model
includ
nonhuman
primat
use
vaccin
origin
restrict
peopl
high
risk
infect
ie
farm
worker
design
highrisk
area
laboratori
personnel
industri
worker
close
contact
raw
anim
materi
hide
wool
bone
observ
data
efficaci
durat
immun
human
one
control
epidemiolog
studi
conduct
usa
brachman
et
al
show
protect
group
vaccin
worker
goat
hairspin
mill
group
person
fell
ill
cutan
anthrax
wherea
placebo
control
group
peopl
develop
cutan
anthrax
peopl
develop
inhal
anthrax
addit
case
inhal
anthrax
placebo
group
discount
individu
withdrew
trial
protect
properti
biothrax
tm
british
vaccin
appear
similar
unfortun
immun
thought
quit
shortliv
annual
booster
recommend
vaccin
might
expect
rather
oldfashion
vaccin
complex
acellular
protein
vaccin
number
inher
problem
name
unknown
durat
protect
immun
well
number
clinic
relev
side
effect
local
pain
inflamm
site
inject
occasion
fever
gener
malais
new
subunit
vaccin
compris
purifi
pa
rpa
combin
aluminiumbas
adjuv
current
develop
expect
licens
near
futur
vaccin
welldefin
consist
composit
well
toler
initi
two
slightli
differ
type
rpa
vaccin
produc
vaxgen
inc
usa
avecia
uk
undergo
acceler
develop
us
bioshield
program
howev
although
clinic
trial
vaxgen
rpa
vaccin
show
safe
immunogen
gors
et
al
us
govern
contract
suppli
stockpil
vaccin
withdrawn
decemb
rpa
vaccin
unlik
induc
longer
last
protect
immun
exist
licens
protein
vaccin
moreov
also
direct
b
anthraci
toxin
address
problem
septicaemia
experi
type
vaccin
research
anim
particular
guinea
pig
immunesuppress
inbr
mous
strainsshow
abil
induc
longlast
protect
immun
larg
popul
includ
individu
weaken
immun
system
question
reason
seem
imper
effort
increas
antigen
vaccin
exampl
inclus
spore
antigen
use
improv
adjuv
continu
especi
view
increas
deploy
vaccin
among
militari
personnel
laboratori
clinic
staff
furthermor
research
role
innat
immun
mechan
necessari
elimin
pathogen
past
larg
neglect
equal
necessari
past
year
numer
research
effort
develop
new
improv
altern
current
use
vaccin
sever
recent
review
provid
excel
overview
current
statu
potenti
futur
anthrax
vaccin
includ
complet
list
refer
past
present
endeavour
field
beyer
littl
bailli
scorpio
et
al
one
strategi
improv
pabas
vaccin
combin
antigen
adjuv
alhydrogel
alhydrogel
known
induc
strong
cell
respons
lead
high
antibodi
titr
elicit
littl
cell
respons
strong
cellular
immun
respons
anthrax
howev
would
benefici
two
reason
first
would
induc
better
immunolog
memori
convent
vaccin
secondli
would
address
problem
septicaemia
develop
anthrax
wherea
immun
respons
base
antibodi
alon
like
protect
princip
toxin
neutralis
approach
develop
novel
anthrax
vaccin
includ
use
recombin
b
subtili
salmonella
viral
vector
plasmid
dna
vehicl
pa
recombin
organ
well
bacteri
dna
use
studi
serv
natur
adjuv
thu
improv
immun
respons
elicit
differ
rout
administ
anthrax
vaccin
current
inject
subcutan
also
investig
novel
approach
focus
mainli
oral
nasal
also
intraderm
applic
rational
behind
research
rout
deliveri
elicit
strong
mucos
immun
respons
thought
give
better
protect
especi
case
inhal
anthrax
variou
research
effort
attempt
identifi
addit
antigen
b
anthraci
protect
properti
antigen
like
basic
outer
structur
spore
eg
bcla
bacterium
eg
polygdglutam
acid
capsul
also
toxin
factor
lf
nonbiolog
activ
form
use
combin
pa
interestingli
capsulepa
conjug
vaccin
induc
strong
bactericid
opson
antibodi
respons
schneerson
et
al
rhie
et
al
protect
provid
spore
immunis
reli
cellmedi
immun
involv
tlymphocyt
secret
ifng
absolut
prerequisit
effect
protect
glomski
et
al
b
thu
combin
sporereact
cell
immun
toxinneutralis
humor
immun
result
enhanc
protect
b
anthraci
infect
combin
b
anthraci
fi
recombin
pa
proven
particularli
effect
protect
laboratori
anim
anthrax
brossier
et
al
recent
year
avail
complet
dna
sequenc
sever
strain
b
anthraci
use
proteom
transcriptom
exampl
driven
continu
drive
search
novel
antigen
use
anthrax
vaccin
given
sensit
specif
assay
avail
determin
immun
respons
relat
develop
anthrax
vaccin
antitoxin
immunotherapeut
straightforward
reli
robust
assay
readout
use
reagent
highest
qualiti
immun
correl
protect
cop
anthrax
known
certain
although
antitoxin
antitoxin
compon
respons
import
inde
secondgener
subunit
vaccin
base
rpa
cop
combin
antibodi
titr
function
respons
exampl
affin
neutralis
capac
contrast
cop
livespor
vaccin
eg
sti
vaccin
base
adjuv
acellular
cultur
filtrat
eg
licens
uk
us
acellular
anthrax
vaccin
novel
development
combin
vaccin
eg
institut
pasteur
rpa
plu
fi
vaccin
multigen
plasmid
dna
vaccin
inevit
complex
differ
subtli
one
anoth
develop
new
vaccin
formul
approach
continu
apac
need
prepar
assess
suitabl
vaccin
human
use
facilit
exchang
bestpractic
assay
reagent
harmonis
approach
assess
immun
respons
antiigg
isotyp
subclass
assay
assay
use
quantifi
immun
respons
individu
human
anim
vaccin
diagnosi
assay
quantifi
specif
antibodi
commonli
immunoglobulin
g
igg
antibodi
use
elisa
purifi
rpa
rlf
use
solidphas
immobilis
antigen
enzymeconjug
antihuman
anim
gamma
chain
antibodi
use
report
system
order
detect
paand
lfspecif
igg
use
altern
conjug
allow
determin
differ
isotyp
igm
iga
igg
subclass
report
valu
antibodi
titr
andor
mgml
concentr
calibr
refer
serum
avail
avid
specif
antibodi
also
determin
elisa
use
increas
concentr
chaotrop
eg
ammonium
thiocyan
urea
elut
antibodi
bound
complex
microtitr
plate
fix
igg
concentr
provid
avid
index
surrog
affin
bind
constant
particular
antibodi
prepar
serum
compris
popul
antibodi
vari
bind
affin
precis
determin
bind
affin
made
studi
analyteligand
antigenantibodi
interact
use
surfac
plasmon
reson
eg
biacor
toxin
neutralis
assay
tna
b
anthraci
lt
capabl
intox
lyse
certain
wellcharacteris
monocytemacrophag
cell
line
commonli
murin
macrophag
cell
line
intox
may
neutralis
serum
purifi
antibodi
immunis
subject
thu
toxin
neutralis
assay
tna
use
assess
antibodi
function
basi
avail
inform
b
anthraci
infect
anthrax
toxin
challeng
experiment
model
function
immun
respons
appear
central
protect
therefor
defin
import
cop
howev
rel
contribut
neutralis
respons
due
differ
antibodi
fraction
isotyp
subclass
direct
pa
andor
lf
epitop
thereon
seldom
consid
specif
tna
design
measur
quantifi
function
abil
antipa
antilf
antisera
neutralis
lethal
toxin
activ
use
vitro
cytotox
assay
cell
viabil
determin
colourimetr
use
tetrazolium
salt
report
system
mosmann
here
et
al
serummedi
neutralis
anthrax
lethal
toxin
manifest
suppress
lysi
result
increas
cell
viabil
assay
endpoint
report
reciproc
dilut
serum
sampl
result
neutralis
anthrax
lethal
toxin
toxin
compon
specif
sensit
qualifi
elisabas
assay
anthrax
toxin
compon
pa
lf
develop
determin
composit
anthrax
vaccin
exampl
uk
health
protect
agenc
appli
assay
variou
stage
manufactur
uk
licens
acellular
anthrax
vaccin
addit
assay
util
diagnosi
natur
occur
diseas
follow
deliber
releas
sandwich
elisa
consist
plate
coat
polyclon
antibodi
design
captur
relev
antigen
sampl
detect
similar
antibodi
conjug
recent
mabri
et
al
report
novel
experiment
sandwich
elisa
assay
pa
lf
pa
elisa
either
singl
chain
fv
mous
monoclon
antibodi
solubl
form
extracellular
domain
anthrax
toxin
receptor
use
captur
agent
lf
elisa
use
pa
captur
agent
unfortun
lf
ef
abl
bind
competit
pa
oligom
assay
would
also
captur
ef
present
cours
relev
efcontain
vaccin
macrophag
cell
lysi
assay
lt
macrophag
cell
lysi
assay
use
measur
function
activ
b
anthraci
lethal
toxin
also
measur
activ
individu
toxin
compon
ie
pa
lf
cultur
supernat
anthrax
vaccin
spike
sampl
fix
amount
lf
pa
separ
experi
endopeptidas
assay
lf
lf
zn
depend
metalloproteas
cleav
inactiv
mitogenactiv
protein
kinas
kinas
princip
duesberi
et
al
vital
et
al
simpl
absorb
assay
develop
base
use
chromogen
peptid
substrat
design
basi
recognit
cleavag
consensu
motif
vital
et
al
tonello
et
al
altern
lf
determin
use
modifi
elisa
plate
coat
synthet
peptid
repres
ntermin
residu
human
recombin
fusion
protein
halli
hudson
unpublish
assay
base
electrochemiluminesc
lf
also
develop
rivera
et
al
although
rather
labori
expens
addit
fluoresc
reson
energi
transfer
assay
lf
requir
low
nanomolar
level
enzym
develop
platebas
assay
screen
potenti
toxin
inhibitor
cum
et
al
method
detect
lf
via
metalloproteas
activ
bias
possibl
proteas
contamin
present
sampl
examin
hydrolys
substrat
lead
fals
posit
ef
assay
assay
ef
activ
either
ca
calmodulindepend
adenyl
cyclas
assay
wide
avail
assay
base
examin
often
transient
morpholog
chang
cell
exposur
efcontain
sampl
studi
cdc
usa
led
develop
fluoresc
coval
microbead
immunosorb
assay
fcmia
antipa
igg
use
luminex
xmap
technolog
fcmia
appear
offer
benefit
elisa
measur
antipa
igg
includ
greater
sensit
speed
enhanc
dynam
rang
reagent
stabil
use
small
sampl
volum
abil
multiplex
measur
one
analyt
simultan
evidenc
multiplex
assay
antipa
igg
antilf
igg
serum
anthrax
patient
biagini
et
al
multiplex
assay
offer
much
potenti
target
analyt
per
sampl
claim
although
valid
procedur
assay
complex
inde
kinet
antibodyantigen
bind
system
target
ligand
bound
coval
fluoresc
label
microbead
subtli
differ
elisa
target
ligand
passiv
randomli
adsorb
plastic
microtitr
plate
greater
dynam
rang
precis
obtain
routin
bioquant
inc
establish
multiplex
diagnost
assay
b
anthraci
infect
human
test
kit
detect
individu
igg
igm
antibodi
pa
singl
patient
sampl
despit
award
grant
fund
develop
multiplex
antigen
elisa
product
yet
avail
bioanalyt
method
use
routin
sampl
test
must
demonstr
sensit
reliabl
reproduc
order
give
highest
level
confid
qualiti
data
obtain
experi
show
technolog
transfer
research
assay
associ
reagent
problemat
larg
assay
partial
develop
optimis
contrast
wellcharacteris
optimis
qualifiedvalid
document
assay
far
robust
transfer
well
close
scrutini
equip
reagent
procedur
afford
level
confid
requir
assay
use
clinic
set
diagnost
pharmaceut
develop
sampl
test
aris
clinic
trial
work
nonclin
studi
support
product
releas
like
requir
test
within
glpgcp
good
laboratori
practicegood
clinic
practic
socal
gxp
environ
howev
step
requir
essenti
gener
qualiti
system
eg
gmp
good
manufactur
practic
differ
larg
accord
level
detail
whilst
assay
undergo
formal
prequalif
qualif
procedur
requir
valid
includ
run
formal
valid
protocol
equip
within
sampl
test
laboratori
procedur
care
extens
document
portfolio
document
subject
close
scrutini
assessor
relev
qualiti
system
europ
usa
defin
intern
confer
harmonis
guidelin
ich
steer
committe
valid
qualif
involv
demonstr
particular
method
use
quantit
measur
analyt
given
biolog
matrix
accur
ii
precis
iii
specif
iv
sensit
v
reproduc
across
time
analyst
vi
robust
vii
stabl
term
differ
reagent
batch
detail
process
beyond
scope
review
well
defin
variou
regulatori
convent
assay
use
across
multipl
laboratoriessit
requir
formal
procedur
technolog
transfer
order
demonstr
satisfactori
level
intersit
precis
accuraci
first
foremost
train
process
avail
adequ
characteris
reagent
first
critic
step
promot
harmonis
method
across
site
standard
oper
procedur
sop
method
must
also
freeli
avail
fig
site
involv
transfer
perform
method
use
differ
oper
determin
level
success
transfer
ensur
equival
result
obtain
differ
equip
analyst
use
often
profici
panel
test
sampl
known
level
perform
run
across
variou
site
requir
method
may
need
modifi
finalis
sop
agre
upon
across
site
method
demonstr
success
transfer
individu
site
requir
bridg
new
batch
reagent
readili
avail
given
major
role
toxin
pathogenesi
anthrax
identif
specif
inhibitor
pa
ef
lf
anoth
import
strategi
follow
order
develop
novel
effect
therapeut
compar
mani
studi
focuss
proteolyt
activ
lf
pa
ef
within
anthrax
euronet
project
green
tea
extract
rich
polyphenol
found
contain
sever
good
inhibitor
lf
vitro
vivo
best
ecgc
dellaica
et
al
recent
branch
peptid
found
inhibit
ef
lf
bind
pa
pini
et
al
exampl
power
inhibitor
ef
adefovir
dipivoxil
shen
et
al
use
egcg
adefovir
alon
combin
antibiot
assess
possibl
therapeut
role
potent
inhibitor
anthrax
toxin
howev
found
protect
given
earli
phase
infect
fasanella
et
al
unpublish
suggest
role
toxin
critic
initi
patholog
therapi
toxin
inhibitor
alon
clear
infect
insuffici
fasanella
et
al
unpublish
rather
combin
procedur
appropri
antibiot
treatment
postexposur
vaccin
highli
promis
inhibitor
lf
differ
chemic
categori
biolog
origin
adefensin
produc
variou
cell
human
anim
bodi
part
innat
immun
defenc
kim
kaufmann
particular
adefensin
mainli
releas
neutrophil
via
exocytosi
azurophil
granul
strong
inhibitor
lf
metalloproteas
activ
toxic
mice
kim
et
al
kim
kaufmann
similar
activ
also
report
retrocyclin
relat
ydefensin
wang
et
al
therapeut
potenti
potent
cation
peptid
anthrax
remain
establish
part
consortium
activ
anthrax
euronet
consortium
organis
unpreced
intern
symposium
bring
togeth
research
fund
agenc
public
health
privat
sector
repres
polici
make
bodi
eu
distinguish
guest
multidisciplinari
field
intersect
issu
bioterror
biodef
biosecur
key
topic
cover
includ
state
art
anthrax
research
histori
psycholog
biodef
research
approach
intern
biorisk
reduct
code
conduct
dualus
issu
best
practic
practic
implement
scientif
educ
fund
agenc
publish
symposium
outcom
reflect
current
statu
issu
discuss
problem
challeng
solut
conclud
bwc
review
confer
decemb
made
sever
pivot
recommend
state
terrorist
must
prevent
develop
produc
stockpil
otherwis
acquir
retain
use
circumst
biolog
agent
toxin
nonpeac
purpos
also
consid
import
facilit
econom
technolog
develop
intern
cooper
field
peac
biolog
activ
clearli
confer
recogn
import
code
conduct
self
regulatori
mechan
rais
awar
call
upon
state
parti
support
encourag
develop
promulg
adopt
discuss
restrict
dualus
organ
b
anthraci
also
emphasis
natur
outbreak
infecti
diseas
major
threat
nation
prepared
contribut
intern
capabl
respons
investig
mitig
outbreak
diseas
thu
made
clear
code
conduct
longer
focuss
intent
releas
microorgan
also
integr
unintent
releas
well
natur
outbreak
infecti
diseas
bwc
recommend
sixth
review
confer
state
parti
convent
prohibit
develop
product
stockpil
bacteriolog
biolog
toxin
weapon
destruct
therefor
much
broader
implic
exist
infecti
diseas
malaria
newli
emerg
diseas
acquir
immunodefici
syndrom
sever
acut
respiratori
syndrom
reemerg
diseas
tuberculosi
notabl
multiresist
form
thereof
well
emergingreemerg
pathogen
influenza
pose
much
higher
threat
microorgan
releas
bioterrorist
code
conduct
research
clinician
work
threaten
pathogen
urgent
need
avoid
laboratori
outbreak
intent
unintent
scenario
misus
b
anthraci
bioterrorist
purpos
may
promot
major
shift
awar
highrisk
infecti
agent
need
code
conduct
dualus
research
sever
similar
european
project
continu
work
anthrax
euronet
auspic
scientif
support
polici
preparatori
action
secur
research
fund
line
directorategener
dg
research
well
project
fund
dg
sanco
public
health
programm
expect
outcom
combin
work
project
draft
code
conduct
work
highrisk
pathogen
develop
scientist
biosafeti
expert
draft
document
key
tool
inform
polici
maker
rais
awar
amongst
key
stakehold
research
field
provid
signific
input
balanc
approach
potenti
global
biosecur
measur
futur
approach
emphasis
need
foster
cultur
respons
make
biosecur
routin
part
overarch
safe
procedur
biosafeti
work
microbiolog
laboratori
gener
good
laboratori
practic
manag
